Sergio Harari sul trattamento della linfangioleiomiomatosi (LAM) (in Italian)

from The Lancet Respiratory Medicine in conversation with · host The Lancet Group

Il Professor Sergio Harari commenta i risultati di un trial clinico di fase 2 volto a valutare l’attivita’ e la sicurezza del farmaco nintedanib come trattamento in pazienti affetti da linfangioleiomiomatosi (LAM). Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Episode metadata supplied by the publisher feed · Published Oct 25, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Sergio Harari sul trattamento della linfangioleiomiomatosi (LAM) (in Italian)

0:00 10:40

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Lancet Respiratory Medicine in conversation with?

This episode is 10 minutes long.

When was this The Lancet Respiratory Medicine in conversation with episode published?

This episode was published on October 25, 2024.

Can I download this The Lancet Respiratory Medicine in conversation with episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!